文献速递白血病

靶向B细胞急性淋巴细胞白血病对NAD+耗竭的易感性

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2017-09-14

KPT-9274是PAK4和NAMPT双抑制剂,可强烈抑制B-ALL细胞生长且不受细胞遗传学异常影响,在患者来源异种移植小鼠模型中显示体内疗效和耐受性;烟酸补充可大部分消除该抑制作用,提示其效应主要通过NAMPT抑制导致NAD+耗竭实现。

要点

  • KPT-9274是PAK4和NAMPT双抑制剂,可强烈抑制B-ALL细胞生长。
  • 烟酸补充可大部分消除KPT-9274对B-ALL细胞生长的抑制。
  • B-ALL细胞对NAMPT抑制高度敏感与细胞NAD+储备降低有关。

核心结论

  • NAD+耗竭可能是治疗B-ALL患者的一种有前景的替代方法。

研究设计与样本

  • 研究采用B-ALL细胞系和患者来源异种移植小鼠模型评估KPT-9274的体外和体内效应。

主要发现

  • KPT-9274强烈抑制B-ALL细胞生长,且不受细胞遗传学异常影响。
  • 在患者来源异种移植小鼠模型中,KPT-9274显示强效体内疗效和耐受性。
  • 烟酸补充可大部分消除KPT-9274对B-ALL细胞生长的抑制,提示其抑制效应主要通过NAMPT抑制导致NAD+耗竭实现。
  • B-ALL细胞对NAMPT抑制的极度敏感性与细胞NAD+储备降低有关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although substantial progress has been made in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), the prognosis of patients with either refractory or relapsed B-ALL remains dismal. Novel therapeutic strategies are needed to improve the outcome of these patients. KPT-9274 is a novel dual inhibitor of p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase (NAMPT). PAK4 is a serine/threonine kinase that regulates a variety of fundamental cellular processes. NAMPT is a rate-limiting enzyme in the salvage biosynthesis pathway of nicotinamide adenine dinucleotide (NAD) that plays a vital role in energy metabolism. Here, we show that KPT-9274 strongly inhibits B-ALL cell growth regardless of cytogenetic abnormalities. We also demonstrate the potent in vivo efficacy and tolerability of KPT-9274 in a patient-derived xenograft murine model of B-ALL. Interestingly, although KPT-9274 is a dual PAK4/NAMPT inhibitor, B-ALL cell growth inhibition by KPT-9274 was largely abolished with nicotinic acid supplementation, indicating that the inhibitory effects on B-ALL cells are mainly exerted by NAD+ depletion through NAMPT inhibition. Moreover, we have found that the extreme susceptibility of B-ALL cells to NAMPT inhibition is related to the reduced cellular NAD+ reserve. NAD+ depletion may be a promising alternative approach to treating patients with B-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Takao S, Chien W, Madan V, et al. Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28904384. doi:10.1038/leu.2017.281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。